Sustained Unresponsiveness (SU) to Cashew Nut Protein Following Oral Allergen-Specific Immunotherapy

Inclusion Criteria: * Cashew nut allergy confirmed prior to the initiation of immunotherapy * Completion of the first phase of the study, including achievement of the maintenance dose (1200 mg of cashew nut protein) during immunotherapy * Provision of informed consent for participation in the study * Adequate cooperation from the patient and/or their legal guardians Exclusion Criteria: * Severe asthma * Poorly controlled mild-to-moderate asthma, defined as: * FEV1 \< 80% (below the 5th percentile), * FEV1/FVC ratio \< 75% (below the 5th percentile), * Hospitalization due to asthma exacerbation within the past 12 months * Oral, sublingual, or subcutaneous immunotherapy for other allergens during the first year/season of therapy * Eosinophilic gastrointestinal disorders * Severe, recurrent episodes of anaphylaxis within the last 6 months * Chronic illnesses requiring ongoing treatment, including: * Cardiac conditions * Epilepsy * Metabolic disorders * Diabetes mellitus * Use of the following medications: * Daily oral corticosteroid therapy \>1 month within the past 12 months * At least two courses of oral corticosteroids (minimum duration of 7 days each) in the past 12 months * One course of oral corticosteroids (minimum 7 days) within the past 3 months * Biologic therapies * Treatment with β-blockers, ACE inhibitors, or calcium channel blockers * Pregnancy * Lack of informed consent for participation * Lack of cooperation from the patient